Imperial College London

Dr Mark P. Lythgoe

Faculty of MedicineDepartment of Surgery & Cancer

Research Postgraduate
 
 
 
//

Contact

 

m.lythgoe

 
 
//

Location

 

Institute of Reproductive and Developmental BiologyHammersmith Campus

//

Summary

 

Publications

Publication Type
Year
to

96 results found

Khanna S, Sarwar N, Caldwell R, Krell J, Benjamin DJ, Hadfield MJ, Khaki AR, Warner JL, Lythgoe Met al., 2024, Regulatory approvals for genitourinary (GU) cancer by the Food and Drug Administration (FDA) and European Medicines Agency (EMA) over 20 years (2003-2023)., Journal of Clinical Oncology, Vol: 42, Pages: 432-432, ISSN: 0732-183X

<jats:p> 432 </jats:p><jats:p> Background: The past 2 decades has witnessed a transformation in the GU cancer therapy armamentarium. In this study, we analysed GU cancer therapy approvals (initial &amp; supplemental) by the two largest global regulators (EMA and FDA) by evaluating approval timing, labels, biomarker requirements and drug withdrawal(s). Methods: A cross-sectional analysis of approved drugs and indications made for GU cancer medicines from each regulatory database from 2003-2023 was performed. We compared new approved therapies, indications and biomarker requirements. Results: The FDA approved 40 new therapies, corresponding to 57 indications, with 2 withdrawals. The EMA approved 33 new therapies, corresponding to 43 indications with 1 withdrawal. Overall, the FDA approved new GU cancer therapies 128 days earlier (table). In renal cell carcinoma (RCC), the FDA approved 14 new therapies across 18 indications, compared to 14 new therapies across 16 indications for the EMA. The FDA approved new RCC therapies 113 days earlier than the EMA. For concomitant approvals the FDA label was broader for 5 indications, more restrictive for 2 and equivocal for 9. In urothelial cancer (UC), the FDA approved 9 new therapies across 14 indications, compared to 7 new therapies across 7 indications for the EMA. The FDA approved new UC therapies 110 days earlier than the EMA. For concomitant approvals, the FDA label was broader for 4 indications and equivocal for 3. In prostate cancer (PC), the FDA approved 17 new therapies across 25 indications, compared to 12 new therapies across 20 indications for the EMA. The FDA approved new PC therapies 157 days earlier than the EMA. For concomitant approvals, the FDA label was broader for 2 indications and equivocal for 18. Across GU cancer, 8 therapies (both FDA and EMA) had biomarker-based eligibility with 3 notable differences in urothelial cancer: the EMA uniquely requires a PD-L1 combined positive score (CP

Journal article

Benjamin DJ, Lythgoe MP, Kalebasty AR, 2024, Hollywood's Take on Oncology: Portrayal of Cancer in Movies, 2010-2020., JCO Oncol Pract

Journal article

Jenei K, Lythgoe MP, Vokinger KN, 2024, Shortages of essential cancer medicines: who is responsible and what are the possible solutions?, Lancet Oncol, Vol: 25, Pages: 23-26

Journal article

Harris BHL, Mccabe C, Shafique H, Lammy S, Tookman L, Flanagan J, Miron-Barroso S, Lythgoe M, Clark J, Walsh JL, Di Giovannantonio M, Krell Jet al., 2024, Diversity of thought: public perceptions of genetic testing across ethnic groups in the UK, Journal of Human Genetics, Vol: 69, Pages: 19-25, ISSN: 1434-5161

Genetic testing is becoming rapidly more accessible to the general populous either through or outside healthcare systems. Few large-scale studies have been carried out to gauge public opinion in this growing area. Here, we undertook the largest cross-sectional study on genetic testing in the UK. The primary purpose of this study is to identify the differences in attitudes toward genetic testing across ethnic groups. A cohort of 6500 individuals from a diverse population completed a 72-item survey in a cross-sectional study. Responses between ethnic minority and white individuals in the UK were compared using a wilcoxon rank-sum and chi-square tests. The white cohort was approximately twice as likely to have taken a genetic test and 13% more had heard about genetic testing before the survey. The ethnic minority cohort appeared more apprehensive about the impact of genetic testing on employability. This study highlights that in the UK, significant differences in opinions regarding genetic testing exist between white individuals and ethnic minority individuals. There is an urgent need to develop more inclusive strategies to equally inform individuals from all backgrounds to avoid disparities in the utilisation of genetic testing.

Journal article

Julve M, Kennedy O, Frampton AE, Bagwan I, Lythgoe MPet al., 2023, Gene of the month: cancer testis antigen gene 1b (NY-ESO-1)., J Clin Pathol, Vol: 77, Pages: 1-7

Cancer testis antigen gene 1B (CTAG1B) and its associated gene product; New York oesophageal squamous carcinoma 1 (NY-ESO-1), represent a unique and promising target for cancer immunotherapy. As a member of the cancer testis antigen family (CTA), the protein's restricted expression pattern and ability to elicit spontaneous humoural and cellular immune responses has resulted in a plethora of novel modalities and approaches attempting to harness its immunotherapeutic anti-cancer potential. Here, we discuss the structure and function of CTAG1B/NY-ESO-1 in both health and disease, immunohistochemical detection, as well as the most promising advances in the development of associated anti-cancer therapies. From cancer vaccines to engineered cellular therapy approaches, a multitude of immunotherapies targeting CTA's are coming to the forefront of oncology. Although the efficacy of such approaches have yet to provide convincing evidence of durable response, early phase clinical trial data has resulted in some exciting findings which will have significant potential to act as a platform for future practice changing technologies.

Journal article

Benjamin DJ, Shrestha A, Fellman D, Cress RD, Lythgoe MP, Rezazadeh Kalebasty Aet al., 2023, Correction: Hormonal treatment for newly diagnosed metastatic prostate cancer: a population-based study from the California cancer registry., Prostate Cancer Prostatic Dis

Journal article

Benjamin DJ, Shrestha A, Fellman D, Cress RD, Lythgoe MP, Rezazadeh Kalebasty Aet al., 2023, Hormonal treatment for newly diagnosed metastatic prostate cancer: a population-based study from the California cancer registry., Prostate Cancer Prostatic Dis

INTRODUCTION: To evaluate how often men with metastatic prostate cancer (mPC) receive standard of care treatment with androgen deprivation therapy (ADT). METHODS: Men aged ≥20 years with newly diagnosed mPC (stage IV) between 2010 and 2018 were identified using California Cancer Registry data. Receipt of hormonal therapy as initial cancer treatment was examined by patient/tumor characteristics at time of diagnosis. Chi-square tests and logistic regression, adjusted for covariates, were performed to assess association between receipt of hormonal therapy and patient/tumor characteristics. RESULTS: We identified 13,680 men with newly diagnosed mPC, of which 3637 had local metastasis (N1) only while 9596 had distant metastasis (M1) with or without N1 disease. 21.8 % (n = 2980) of men did not receive ADT. The highest rate of receiving ADT was among men between ages 75-84 (81.6%) and the lowest rate was in men over 85 (76.0%). Asian men had the largest proportion receiving ADT (n = 962, 81.5%) with remaining subgroups having similar proportion of men receiving ADT (76.8% to 77.2%). Once adjusted for covariates, regression results showed men with a higher Gleason score (8-10) were more likely to receive ADT (OR 2.04, 1.82-2.27, p = < 0.001) as well as men with distant sites of metastatic disease (OR 4.02, 3.62-4.46, p = < 0.001). Men residing in neighborhoods with the lowest socioeconomic status were least likely to receive ADT (OR 0.79, 0.68-0.93, p = 0.0032). No differences in receipt of ADT were observed by race/ethnicity. DISCUSSION: Despite significant advancements in the treatment of mPC in recent years, over one-fifth of patients did not receive ADT, which is the backbone for all new systemic therapies. This dataset might help address some of the prostate cancer care disparities in California.

Journal article

Lythgoe M, Sullivan R, Blagden S, 2023, UK oncology approvals in 2022: global regulatory collaboration and new regulatory pathways deliver New anti-cancer therapies, The Lancet Oncology, Vol: 24, Pages: 963-966, ISSN: 1213-9432

Journal article

Lythgoe M, 2023, Another setback for cancer research in the UK, BMJ: British Medical Journal, ISSN: 0959-535X

Journal article

Aboagye E, Aravind P, Popat S, Barwick TD, Soneji N, Lythgoe M, Sreter KB, Lozano- Kuehne JP, Bergqvist M, Patel N, Kenny LMet al., 2023, A subset of non-small cell lung cancer patients treated with pemetrexed show 18f-fluorothymidine ‘flare’ on positron emission tomography, Cancers, Vol: 15, Pages: 1-14, ISSN: 2072-6694

Thymidylate synthase (TS) remains a major target for cancer therapy. TS inhibition elicits increases in DNA salvage pathway activity, detected as a transient compensatory “flare” in 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography (18F-FLT PET). We determined the magnitude of the 18F-FLT flare in non-small cell lung cancer (NSCLC) patients treated with the antifolate pemetrexed in relation to clinical outcome. Method: Twenty-one patients with advanced/metastatic non-small cell lung cancer (NSCLC) scheduled to receive palliative pemetrexed ± platinum-based chemotherapy underwent 18F-FLT PET at baseline and 4 h after initiating single-agent pemetrexed. Plasma deoxyuridine (dUrd) levels and thymidine kinase 1 (TK1) activity were measured before each scan. Patients were then treated with the combination therapy. The 18F-FLT PET variables were compared to RECIST 1.1 and overall survival (OS). Results: Nineteen patients had evaluable PET scans at both time points. A total of 32% (6/19) of patients showed 18F-FLT flares (>20% change in SUVmax-wsum). At the lesion level, only one patient had an FLT flare in all the lesions above (test–retest borders). The remaining had varied uptake. An 18F-FLT flare occurred in all lesions in 1 patient, while another patient had an 18F-FLT reduction in all lesions; 17 patients showed varied lesion uptake. All patients showed global TS inhibition reflected in plasma dUrd levels (p < 0.001) and 18F-FLT flares of TS-responsive normal tissues including small bowel and bone marrow (p = 0.004 each). Notably, 83% (5/6) of patients who exhibited 18F-FLT flares were also RECIST responders with a median OS of 31 m, unlike patients who did not exhibit 18F-FLT flares (15 m). Baseline plasma TK1 was prognostic of survival but its activity remained unchanged following treatment. Conclusions: The better radiological response and longer survival observed in patients with an 18F-FLT flare suggest the

Journal article

Lythgoe M, Sullivan R, 2023, Outsourcing UK regulatory decisions – A double edged sword?, The Lancet, Vol: 402, Pages: 24-25, ISSN: 0140-6736

Journal article

Lythgoe M, 2023, The evidence base of US Food and Drug Administration approvals of novel cancer therapies from 2000 to 2020, International Journal of Cancer, Vol: 152, Pages: 2474-2484, ISSN: 0020-7136

Concerns have been raised that regulatory programs to accelerate approval of cancer drugs in cancer may increase uncertainty about benefits and harms for survival and quality of life (QoL). We analyzed all pivotal clinical trials and all non-pivotal randomized controlled trials (RCTs) for all cancer drugs approved for the first time by the FDA between 2000 and 2020. We report regulatory and trial characteristics. Effects on overall survival (OS), progression-free survival and tumor response were summarized in meta-analyses. Effects on QoL were qualitatively summarized. Between 2000 and 2020, the FDA approved 145 novel cancer drugs for 156 indications based on 190 clinical trials. Half of indications (49%) were approved without RCT evidence; 82% had a single clinical trial only. OS was primary endpoint in 14% of trials and QoL data were available from 25%. The median OS benefit was 2.55 months (IQR, 1.33-4.28) with a mean hazard ratio for OS of 0.75 (95%CI, 0.72-0.79, I2 = 42). Improvement for QoL was reported for 7 (4%) of 156 indications. Over time, priority review was used increasingly and the mean number of trials per indication decreased from 1.45 to 1.12. More trials reported results on QoL (19% in 2000-2005; 41% in 2016-2020). For 21 years, novel cancer drugs have typically been approved based on one single, often uncontrolled, clinical trial, measuring surrogate endpoints. This leaves cancer patients without solid evidence that novel drugs improve their survival or QoL and there is no indication towards improvement.

Journal article

Lythgoe M, Lewison G, Aggarwal AK, Booth CM, Lawler M, Trapani D, Sengar M, Sullivan Ret al., 2023, A bibliometric analysis of immuno-oncology research: Is a new global leader emerging?, Journal of Clinical Oncology, Vol: 41, Pages: e13593-e13593, ISSN: 0732-183X

<jats:p> e13593 </jats:p><jats:p> Background: The last decade has witnessed an increase in cancer research globally, and a transformation of the anti-cancer armamentarium. The biggest innovation has been development of immuno-oncology (IO) therapies, and specifically immune checkpoint inhibitors (ICIs), targeting CTLA-4 and PD-(L)1, reshaping treatment paradigms for many cancers (e.g., melanoma). Since the first ICI approval in 2011, research from countries in the European Union (EU) and North America has dominated this field. However, more recently research authored in China has emerged as a potential leader. In this study we analysed cancer and IO research outputs since 2011, exploring emerging national trends, and focusing on ICI development. Methods: IO research articles were identified using a high-resolution bibliometric method, previously validated. Relevant articles were identified from the Web of Science, utilising a complex search strategy of pre-defined keywords, including the 9 FDA-approved ICI and 8 ICI approved in China-only. Additional search filters were used to determine secondary characteristics including country (assigned a fractional count based on proportional authorship), collaborations, and tumour site. Results: Since 2011, over 175,000 cancer research articles have been published globally. The number of articles published annually has increased steadily, largely driven by increasing outputs from Chinese authors. China is now the leading global publisher of cancer research accounting for 18% of all outputs in 2021, and has consistently surpassed US and EU total outputs since 2019. Over the past decade there has been a steady increase in total IO research outputs, rising by 378% (n = 2926) compared to 2011. China began publishing significant IO research in 2014 and has risen rapidly to dominate this field. In 2021, China accounted for 37% of total IO outputs. The US was previously dominant, however there has been a steady decl

Journal article

Lythgoe M, Dama P, Frampton AE, Pickford E, Tookman L, Cunnea P, Fotopoulou C, Liu D, Clark J, Lozano-Kuehne J, Badman PD, Clarke A, Chetal S, Fyvie G, Stevenson A, Krell Jet al., 2023, Immune modulation and the oral live biotherapeutic product, MRx0518, in treatment-naive patients with cancer: Updated safety data, Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Publisher: LIPPINCOTT WILLIAMS & WILKINS, ISSN: 0732-183X

Conference paper

Lythgoe M, Dama P, Frampton AE, Pickford E, Tookman L, Cunnea P, Fotopoulou C, Liu D, Clark J, Lozano-kuehne J, Badman PD, Clarke A, Chetal S, Fyvie G, Stevenson A, Krell Jet al., 2023, Immune modulation and the oral live biotherapeutic product, MRx0518, in treatment-naïve patients with cancer: Updated safety data., Journal of Clinical Oncology, Vol: 41, Pages: 3145-3145, ISSN: 0732-183X

<jats:p> 3145 </jats:p><jats:p> Background: Live biotherapeutic products (LBPs) are emerging novel anti-cancer therapies. MRx0518 is a gut microbiome-derived oral LBP, consisting of a single strain of Enterococcus gallinarum, which has demonstrated potent anti-tumorigenic efficacy pre-clinically. We have previously shown MRx0518 monotherapy is associated with significant genomic, immune, microbiome, and metabolomic changes, consistent with anti-cancer efficacy in treatment-naïve patients. Here, we report long-term subject follow-up, and further signals of immune modulatory changes from flow cytometry analysis. Methods: NCT03934827 is a Phase 1B single-centre study in treatment-naive patients with confirmed cancer, planned for surgical resection. 17 patients (8 breast, 4 prostate, 3 uterine, 1 bladder &amp; 1 melanoma) received MRx0518 (1x10<jats:sup>10</jats:sup>-1x10<jats:sup>11</jats:sup>CFU) BID monotherapy for 7-28 days from inclusion until surgery. Safety data was collected from dosing until 1-year following cessation. Exploratory analysis included evaluation of pre- and post-treatment peripheral blood mononuclear cells (PBMCs) by multiparametric flow cytometry for leucocyte activation, indicative of anti-cancer efficacy. Results: A total of 29 adverse events (AEs), all CTCAE grade 1 (96%) and grade 2 (4%), were reported. Only 8 (28%) were deemed related to MRx0518. No grade 3/4 toxicities or serious AEs were recorded. At 30-days, and 1-year follow-up no further serious AEs occurred. At a median follow-up of 41 months, 13 (76%) patients remain cancer-free, with 2 (11%) reoccurrences and 2 (11%) lost to follow-up. Analysis of pre- and post-treatment PBMCs identified statistically significant increases in CD3<jats:sup>+</jats:sup>CD56<jats:sup>+</jats:sup> (p&lt;0.0005), natural killer cells (p&lt;0.005), natural killer T-cells (p&lt;0.01), CD8<jats:sup>+</jats:sup>

Journal article

Lythgoe M, 2023, The FDA’s latest draft guidance on accelerated approvals — one step forward, two steps back?, Nature Reviews Clinical Oncology, Vol: 20, Pages: 577-578, ISSN: 1759-4782

Journal article

Lythgoe M, Lewison G, Aggarwal A, Booth C, Lawler M, Trapani D, Sengar M, Sullivan Ret al., 2023, The rise of immuno-oncology in China - a challenge to western dominance?, The Lancet Oncology, Vol: 24, Pages: 439-441, ISSN: 1213-9432

Journal article

Rizwan N, Pottinger D, Singh R, Jatwani K, Khosla A, Michaeli DT, Michaeli T, Warner J, Lythgoe MP, Khaki AR, Desai Aet al., 2023, 216P Differences in immune checkpoint inhibitor (ICI) approvals made by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for thoracic malignancies, Journal of Thoracic Oncology, Vol: 18, Pages: S156-S156, ISSN: 1556-0864

Journal article

Rizwan N, Pottinger D, Singh R, Jatwani K, Khosla A, Michaeli DT, Michaeli T, Warner J, Lythgoe MP, Khaki AR, Desai Aet al., 2023, Differences in immune checkpoint inhibitor (ICI) approvals made by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for thoracic malignancies, Publisher: ELSEVIER SCIENCE INC, Pages: S156-S156, ISSN: 1556-0864

Conference paper

Lythgoe M, Krell J, Bower M, Murphy R, Marriott J, Blagden SP, Aggawal A, Sullivan Ret al., 2023, From the European Medicines Agency to Project Orbis: new activities and challenges to facilitate UK oncology drug approval following Brexit, The Lancet Oncology, Vol: 24, Pages: e150-e160, ISSN: 1213-9432

The departure of the UK from the European Union (EU) and affiliated European regulatory bodies on the 31st December 2020, including the European Medicines Agency, (EMA), has resulted in the Medicines and Healthcare products Regulatory Agency (MHRA) becoming an independent national regulator. This has required a fundamental transformation of the UK drug regulatory landscape, creating both opportunities and challenges for future oncology drug development. New UK pharmaceutical policy has sought to establish the UK as an attractive market for drug development and regulatory review, by offering expedited review pathways coupled to strong collaborative relations with other leading international medicines regulators, outside of Europe. Oncology is a key global therapy area for both drug development and regulatory approval, and the UK government has been keen to demonstrate regulatory innovation and international collaboration in the approval of new cancer medicines. In this review, we examine the new UK regulatory frameworks, policies, and global collaborations affecting new oncology drug approvals following departure from the EU. We explore some of the challenges which may lie ahead as the UK forges ahead with new and independent regulatory review and approval processes for the next generation of cancer medicines.

Journal article

Benjamin DJ, Lythgoe M, Rezazadeh A, 2023, Financial toxicity from newly approved second-/third-line agents in metastatic urothelial carcinoma, BJU International, Vol: 131, Pages: 691-693, ISSN: 1464-4096

Journal article

Lythgoe M, 2023, Modernising the US FDA's Accelerated Approval pathway, The Lancet Oncology, Vol: 24, Pages: 203-205, ISSN: 1470-2045

On Dec 29, 2022, US President Joe Biden signed The Consolidated Appropriations Act into law. This wide-reaching Act contains notable reforms to the US Food and Drug Administration (FDA) statutory and regulatory frameworks. The legislation amends key regulatory frameworks, including changes to the FDA-expedited approval programme, Accelerated Approval. 1 This pathway has been substantial for drug development globally since its introduction in 1992, permitting early regulatory approval based on surrogate endpoints likely to predict clinical benefit for drugs treating serious or life-threatening conditions. 2 A further confirmatory study is typically required to validate true clinical benefit to permit conversion to standard approval, or in the case of a negative result, potentially medicine withdrawal. Recent scrutiny of the Accelerated Approval pathway, particularly after the approval of aducanumab for Alzheimer's disease, and the notable withdrawal of several cancer medicines (eg, bevacizumab in breast cancer), has led many to call for urgent reform of this pathway. 3 , 4 As Accelerated Approval is predominately used in oncology, with cancer drugs accounting for 85% of use over the past decade, reforms are highly relevant for new cancer drug development and approval. 2 We will therefore highlight key reforms, and potential opportunities and challenges these could present.

Journal article

Blagden SP, Yu L-M, Ellis S, Hughes H, Shaaban A, Fennelly-Barnwell J, Lythgoe MP, Cooper AM, Maignen FM, Buckland SW, Kearns PR, Brown LC, Experimental Cancer Medicine Centres ECMC CID trials working groupet al., 2023, Additional consensus recommendations for conducting complex innovative trials of oncology agents: a post-pandemic perspective, British Journal of Cancer, Vol: 128, Pages: 474-477, ISSN: 0007-0920

In our 2020 consensus paper, we devised ten recommendations for conducting Complex Innovative Design (CID) trials to evaluate cancer drugs. Within weeks of its publication, the UK was hit by the first wave of the SARS-CoV-2 pandemic. Large CID trials were prioritised to compare the efficacy of new and repurposed COVID-19 treatments and inform regulatory decisions. The unusual circumstances of the pandemic meant studies such as RECOVERY were opened almost immediately and recruited record numbers of participants. However, trial teams were required to make concessions and adaptations to these studies to ensure recruitment was rapid and broad. As these are relevant to cancer trials that enrol patients with similar risk factors, we have added three new recommendations to our original ten: employing pragmatism such as using focused information sheets and collection of only the most relevant data; minimising negative environmental impacts with paperless systems; and using direct-to-patient communication methods to improve uptake. These recommendations can be applied to all oncology CID trials to improve their inclusivity, uptake and efficiency. Above all, the success of CID studies during the COVID-19 pandemic underscores their efficacy as tools for rapid treatment evaluation.

Journal article

Khaki AR, Lythgoe MP, Prasad V, 2023, Adjuvant checkpoint inhibitor trials: Is disease-free survival an appropriate endpoint?, Journal of Cancer Policy, Vol: 35, Pages: 1-2, ISSN: 2213-5383

Journal article

Chiang RS, Desai A, Glover MJ, Hui G, Ramchandran KJ, Wakelee H, Lythgoe MP, Khaki ARet al., 2023, Racial diversity and reporting in United States Food and Drug Administration registration trials for thoracic malignancies from 2006-2020, Cancer Investigation, Vol: 41, Pages: 43-47, ISSN: 0735-7907

There is significant racial disparity in thoracic malignancies in terms of epidemiology and outcomes. We analyzed race reporting and racial diversity in the registration trials of drugs approved by the FDA for thoracic malignancies from 2006-2020. We found a significant under-representation of non-white participants in FDA drug registration trials in thoracic malignancies. Furthermore, though almost all trials report some race information, FDA guidelines are not universally followed. There is a disproportionate disease burden of lung cancer in under-represented race communities, and clinical trials should prioritize racial diversity and inclusion efforts.

Journal article

Lythgoe MP, Mullish BH, Frampton A, Krell Jet al., 2022, Polymorphic microbes: a new emerging hallmark of cancer, Trends in Microbiology, Vol: 30, Pages: 1131-1134, ISSN: 0966-842X

Recognition of the microbiome (and ‘polymorphic microbes’ within them) as a new emerging hallmark of cancer reflects a wide body of rapidly evolving research. Microbes may be directly carcinogenic, impact host immune responses to promote malignancy, and key effectors in determining anti-cancer therapy efficacy. Manipulation of the microbiome is showing promise as an opportunity to influence cancer outcomes.

Journal article

Lythgoe M, 2022, No new ‘mabs’ in medicine – New nomenclature for monoclonal antibodies, British Journal of Pharmacology, Vol: 179, Pages: 5338-5339, ISSN: 0007-1188

Journal article

Makrakis D, Talukder R, Diamantopoulos LN, Carril-Ajuria L, Castellano D, De Kouchkovsky I, Koshkin VS, Park JJ, Alva A, Bilen MA, Stewart TF, McKay RR, Santos VS, Agarwal N, Jain J, Zakharia Y, Morales-Barrera R, Devitt ME, Grant M, Lythgoe MP, Pinato DJ, Nelson A, Hoimes CJ, Shreck E, Gartrell BA, Sankin A, Tripathi A, Zakopoulou R, Bamias A, Murgic J, Frobe A, Rodriguez-Vida A, Drakaki A, Liu S, Kumar V, Di Lorenzo G, Joshi M, Isaacsson-Velho P, Buznego LA, Duran I, Moses M, Barata P, Sonpavde G, Yu EY, Wright JL, Grivas P, Khaki ARet al., 2022, Association of prior local therapy and outcomes with programmed-death ligand-1 inhibitors in advanced urothelial cancer, BJU INTERNATIONAL, Vol: 130, Pages: 592-603, ISSN: 1464-4096

Journal article

Lythgoe M, Mullish B, Frampton A, Dama P, Pickford E, Tookman L, Cunnea P, Fotopoulou C, Jeffery I, Fyvie G, Stevenson A, Krell Jet al., 2022, ORAL ADMINISTRATION OF MRX0518 IN TREATMENTNAIVE CANCER PATIENTS IS ASSOCIATED WITH COMPOSITIONAL TAXONOMIC AND METABOLOMIC CHANGES INDICATIVE OF ANTI-TUMORIGENIC EFFICACY, Publisher: BMJ PUBLISHING GROUP, Pages: A659-A659

Conference paper

Rizwan N, Khaki AR, Desai A, Warner J, Krell J, Lythgoe Met al., 2022, 427 Approval timings and review speed of immune checkpoint inhibitors (ICIs) in cancer therapy between the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) from 2010-2022, SITC 37th Annual Meeting (SITC 2022) Abstracts, Publisher: BMJ Publishing Group Ltd

Conference paper

This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.

Request URL: http://wlsprd.imperial.ac.uk:80/respub/WEB-INF/jsp/search-html.jsp Request URI: /respub/WEB-INF/jsp/search-html.jsp Query String: respub-action=search.html&id=00844042&limit=30&person=true